These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18472966)

  • 21. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
    Holsinger FC; Doan DD; Jasser SA; Swan EA; Greenberg JS; Schiff BA; Bekele BN; Younes MN; Bucana CD; Fidler IJ; Myers JN
    Clin Cancer Res; 2003 Aug; 9(8):3183-9. PubMed ID: 12912971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
    Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
    Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
    Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of a novel constitutively active chimeric EGFR to identify new targets for therapy.
    Cheng H; Langley RR; Wu Q; Wu W; Feng J; Tsan R; Fan D; Fidler IJ
    Neoplasia; 2005 Dec; 7(12):1065-72. PubMed ID: 16354589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
    Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.
    Rajput A; Koterba AP; Kreisberg JI; Foster JM; Willson JK; Brattain MG
    Cancer Res; 2007 Jan; 67(2):665-73. PubMed ID: 17234777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S; Ostman A; Rollman O
    Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model.
    Sasaki T; Nakamura T; Rebhun RB; Cheng H; Hale KS; Tsan RZ; Fidler IJ; Langley RR
    Am J Pathol; 2008 Jul; 173(1):205-16. PubMed ID: 18583324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
    Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
    Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
    Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
    Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.
    Korfhagen TR; Le Cras TD; Davidson CR; Schmidt SM; Ikegami M; Whitsett JA; Hardie WD
    Am J Respir Cell Mol Biol; 2009 Nov; 41(5):562-72. PubMed ID: 19244201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer.
    Merchant NB; Voskresensky I; Rogers CM; Lafleur B; Dempsey PJ; Graves-Deal R; Revetta F; Foutch AC; Rothenberg ML; Washington MK; Coffey RJ
    Clin Cancer Res; 2008 Feb; 14(4):1182-91. PubMed ID: 18281553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
    Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
    Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.